Protalix: HOLD Alapkezelo Zrt. reports 5.2% stake

HOLD Alapkezelo Zrt.'s position was measured against 80,571,642 Protalix common shares outstanding as of June 30, 2026.

Rhea-AI Filing Summary

Protalix BioTherapeutics, Inc. (PLX) common shares: HOLD Alapkezelo Zrt., a Hungarian investment fund management company, reported beneficial ownership of 4,157,791 shares, or approximately 5.16% of the common stock; the ownership table reports 5.2%. The calculation is based on 80,571,642 shares outstanding as of June 30, 2026.

HOLD Alapkezelo Zrt. reported sole voting and dispositive power over 4,157,791 shares and shared voting and dispositive power over 0 shares.

Key Figures

Beneficial ownership: 4,157,791 shares Beneficial ownership percentage: Approximately 5.16% Percent of class: 5.2% +2 more

5 metrics

Beneficial ownership 4,157,791 shares HOLD Alapkezelo Zrt. reported amount

Beneficial ownership percentage Approximately 5.16% Percentage stated in the ownership narrative

Percent of class 5.2% Ownership table

Common shares outstanding 80,571,642 shares As of June 30, 2026

Shared voting and dispositive power 0 shares HOLD Alapkezelo Zrt. reported amount

Key Terms

beneficial ownership, Sole Voting Power, Sole Dispositive Power

3 terms

beneficial ownership financial

"beneficial ownership of 4,157,791 shares"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Sole Voting Power financial

"Sole Voting Power 4,157,791.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

Sole Dispositive Power financial

"Sole Dispositive Power 4,157,791.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many PLX shares does HOLD Alapkezelo Zrt. beneficially own?

HOLD Alapkezelo Zrt. reported beneficial ownership of 4,157,791 Protalix common shares, stated as approximately 5.16% of the common stock and 5.2% in the ownership table.

What voting and disposition power does HOLD Alapkezelo Zrt. report for PLX shares?

HOLD Alapkezelo Zrt. reported sole voting and dispositive power over 4,157,791 shares, with shared voting and dispositive power over 0 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/15/2026 - 08:49 AM EDT Accepted by SEC EDGAR 10/15/2026 - 08:48 AM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Protalix BioTherapeutics, Inc.

(Name of Issuer)

Common Shares

(Title of Class of Securities)

74365A309

(CUSIP Number)

10/14/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 74365A309

1

Names of Reporting Persons

HOLD Alapkezelo Zrt.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

HUNGARY

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,157,791.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 4,157,791.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,157,791.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.2 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: Hungarian investment fund management company.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Protalix BioTherapeutics, Inc.
(b)	Address of issuer's principal executive offices: 2 UNIVERSITY PLAZA, SUITE 100, HACKENSACK, NEW JERSEY, 07601
Item 2.
(a)	Name of person filing: HOLD Alapkezelo Zrt. (HUNGARY)
(b)	Address or principal business office or, if none, residence: H-1123 Budapest, Alkotas u. 50., Hungary
(c)	Citizenship: Hungarian
(d)	Title of class of securities: Common Shares
(e)	CUSIP Number(s): 74365A309
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Based upon 80,571,642 shares of the Issuers common stock outstanding as of June 30, 2026, in accordance with 10-Q filed on August 1, 2026.HOLD Alapkezelo Zrt. may have been deemed to have the beneficial ownership of 4,157,791 shares of common stock representing the beneficial ownership of approximately 5.16% of the common stocks.
(b)	Percent of class: 5.2%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: HOLD Alapkezelo Zrt.:4,157,791 shares of Common Stock
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: HOLD Alapkezelo Zrt.:4,157,791 shares of Common Stock
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

HOLD Alapkezelo Zrt.

Signature:	David Pekar
Name/Title:	Chief Investment Officer
Date:	10/15/2026